Orphazyme didn't know buyer before negotiations began
US-based Kempharm, which is set to purchase embattled Orphazyme, was until negotiations began relatively unknown to the Danish firm, according to CEO Anders Vadsholt, who still calls this the best solution considering the firm’s current situation.
by christopher due karlsson, translated by daniel pedersen
Orphazyme, a listed company in Denmark that has been restructuring since in March, did not have any superficial knowledge of its potentially new US-based owner, Kempharm, before entering negotiations.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme sells entire business to US biotech company
For subscribers
.jpg)
.jpg)
.jpg&w=384&q=75)
